Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00389610 · ClinicalTrials.gov registry record · Phase 2
Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT00389610 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 56 participants.
The verdict
NCT00389610, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is an open label, phase II trial study of adjuvant GVAX pancreas vaccine in patients with pancreatic cancer.
Interventions
- BIOLOGICAL GVAX pancreas vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2006-09-11 |
| Est. Completion | 2022-12-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00389610
The ClinicalTrials.gov registry entry for NCT00389610 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GVAX pancreas vaccine is the first listed.
NCT00389610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00389610 about?
NCT00389610 is a clinical study titled "Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer". This is an open label, phase II trial study of adjuvant GVAX pancreas vaccine in patients with pancreatic cancer.
What is the current status of trial NCT00389610?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2006-09-11. Estimated completion is 2022-12-10.
What interventions are being tested in trial NCT00389610?
The interventions under investigation include: GVAX pancreas vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00389610?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.